Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

360
Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
360
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

493
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
493
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.9K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

245
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
245
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

GABA: The Peacekeeper Neurotransmitter-Gut-microbiota Derived Origins and Salivary Biomarker Detection Using Elisa.

Annals of neurosciences·2026
Same author

Performance of Trigger Tools in Identifying Adverse Drug Events in Emergency Intensive Care Unit: A Prospective Observational Study.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2025
Same author

Prevalence of <i>CYP2C19</i> Poor Metabolisers 
Among South Indian Psychiatric Patients: 
A Pharmacogenetic Perspective Toward 
Precision Psychopharmacology.

Annals of neurosciences·2025
Same author

Molecular Docking Studies of <i>Scutellaria baicalensis</i> Targeting HIV Co-Receptor CXCR4.

Current HIV research·2025
Same author

Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature.

Current drug safety·2024
Same author

Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation.

Journal of clinical pharmacology·2022

相关实验视频

Updated: Jan 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

超越森林地块:重新定义基于模型的元分析作为基于模型的药物开发的定量引擎

Bhavatharini Sukumaran1, Rinu Mary Xavier1, Aswathy Vs2

  • 1Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty, Nilgiris, Tamil Nadu, India.

Drug development research
|January 15, 2026
PubMed
概括
此摘要是机器生成的。

基于模型的元分析 (MBMA) 通过将药量计建模与传统元分析相结合,增强药物开发. 这种先进的方法为剂量选择和治疗效果提供了预测性见解,克服了标准证据合成的局限性.

关键词:
贝叶斯的等级模型是贝叶斯的等级模型.基于模型的元分析 (MBMA)模型信息化药物开发 (MIDD)剂量-反应建模.药学指标 药学指标 药学指标 药学指标

更多相关视频

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.3K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.3K

相关实验视频

Last Updated: Jan 16, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.3K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.3K

科学领域:

  • 制药指标 (Pharmacometrics) 是一个指标.
  • 临床试验方法论 临床试验方法论
  • 证据综合 证据综合

背景情况:

  • 传统的元分析在药物开发方面存在局限性,特别是在剂量选择和时间过程动态方面.
  • 基于模型的元分析 (MBMA) 将药量学建模与元分析结合起来,以解决这些局限性.

研究的目的:

  • 批判性地评估MBMA作为一种基于模型的药物开发 (MIDD) 的定量工具.
  • 揭开MBMA的方法论,实际应用,以及它与传统元分析的区别.

主要方法:

  • 总结和合成主要的MBMA技术,包括非线性混合效应建模和贝叶斯层次模型.
  • 讨论模型估计,验证和不确定性量化.
  • 审查治疗领域的应用程序和监管方面的考虑.

主要成果:

  • 通过考虑剂量反应关系,纵向效应和研究间异质性,MBMA提供预测信息.
  • MBMA有助于剂量优化,疗效比较,儿科外推和临床试验设计.
  • MBMA将异构的临床数据转化为可用于药物开发的可操作的见解.

结论:

  • MBMA是一种有价值的,尽管未得到充分利用的,在模型知情药物开发中的技术.
  • 对于定量决策,MBMA比传统的元分析提供了显著的进步.
  • 在整个药物开发生命周期中,MBMA对于利用临床数据至关重要.